Antibodies
2 November 2009
INNATE PHARMA MOVES FORWARD ANTI-KIR MONOCLONAL ANTIBODY IPH 2101 DEVELOPMENT WITH STUDY EXTENSION IN ACUTE MYELOID LEUKEMIA29 October 2009
Micromet and Sanofi-aventis Sign Global Collaboration and License Agreement for New Solid Tumor BiTE Antibody29 October 2009
Regeneron’s Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)29 October 2009
YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG28 October 2009
ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study with Anti-Factor VIII (TB-402)28 October 2009
Novartis biological drug Ilaris® approved in EU to treat children and adults with CAPS, a rare debilitating auto-inflammatory disease27 October 2009
Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer27 October 2009
GSK and Genmab receive accelerated approval for Arzerra26 October 2009
Astellas to Terminate the Development of Anti-Human Osteopontin Antibody ASK8007for RA23 October 2009
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial with Subcutaneous Herceptin(R)21 October 2009
BioWa and NKTT Announce Licensing of BioWa’s POTELLIGENT(R) Technology For Use in Antibody Research and Development21 October 2009
Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer21 October 2009
Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDF’s 20th World Diabetes Congress20 October 2009
Crucell Rabies Monoclonal Antibody Combination: Positive Results Philippines Phase II Study Presented at RITA Conference20 October 2009
MorphoSys and Daiichi Sankyo Forge Alliance to Develop Novel Antibody Therapies against Hospital-Acquired Infections19 October 2009
Trubion Pharmaceuticals, Inc. Reports Positive Data from Phase 2b Re-treatment Study of TRU-01519 October 2009
Phase III Study Showed Two Years of ACTEMRA ® (tocilizumab) Inhibited Progression of Joint Damage and Improved Disease Remission17 October 2009
Genentech and Biogen Idec Receive a Complete Response from FDA for Earlier Use of Rituxan for Rheumatoid ArthritisNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports